echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CITIC Guojian's "Herceptin" monoclonal antibody generic cypriotin obtained clinical approval

    CITIC Guojian's "Herceptin" monoclonal antibody generic cypriotin obtained clinical approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The pace of approval of mAbs is accelerating

    On the morning of May 30, the State Administration of food and Drug Administration reported that the approval status of Domestic Recombinant anti HER2 humanized monoclonal antibody for injection was changed to "approved, to be certified", which means that the heavy weight variety "Herceptin" monoclonal antibody of CITIC Guojian, a joint-stock company of Lansheng, has obtained clinical approval documents and is further away from the product listing

    In addition, according to relevant drug review professionals, new progress has also been made in the application for production approval of CITIC Guojian's siputin

    The review center of the State Food and Drug Administration sent a notice of on-site review in April this year

    That is to say, the company can obtain the production approval document only after the final on-site review

    The above-mentioned approval documents for clinical application are only the four phase clinical trials required by heavy weight new drug approval, involving post marketing evaluation and detection, which is an important progress in the process of new biological drug marketing and production in recent years

    It is reported that the original research drug of CITIC gypsitine is "Herceptin" of Roche pharmaceutical, and the indication is breast cancer, with a cure rate of 95%

    The drug is expensive, with a cost of 32000 US dollars (equivalent to nearly 200000 yuan) for each treatment course

    In 2013, the global sales amount exceeded 6.8 billion US dollars

    According to the pharmaceutical researchers in the securities industry, at present, the domestic McAbs used in cancer only account for less than 5% of the total market share, so the cancer drugs in the research and development stage deserve the most attention

    CITIC Guojian, founded in 2002, launched its main monoclonal antibody product yisaipu in 2005, which is used for ankylosing spondylitis and psoriasis, breaking the monopoly of foreign pharmaceutical enterprises on domestic monoclonal antibody drugs, and has been included in Shanghai medical insurance

    Its market share has expanded year by year

    In addition, in 2011, the company launched genipipa to prevent rejection after organ transplantation, becoming the first target of anti rejection drugs in China

    At present, in addition to the research of "cyprotein", the company also has the treatment of immune rejection of "gentuxi" and the treatment of autoimmune diseases of "linine"

    According to reports, CITIC Guojian was jointly funded by CITIC Group and Lansheng Guojian Pharmaceutical Co., Ltd

    the current equity structure is: CITIC Pacific holds 43.42%, Lansheng Guojian holds 41.69% and Lansheng holds 0.73%

    As Lansheng shares holds 34.65% equity of Lansheng Guojian, Lansheng shares holds 15.18% equity of CITIC Guojian in total.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.